Antithrombotic Therapy After Transcatheter Aortic Valve Replacement In this review, we present the pathophysiological mechanisms of post-transcatheter aortic valve replacement complications and provide updated insights on the rationale behind the various antithrombotic regimens being currently evaluated in large randomized trials
Transcatheter aortic valve implantation: Antithrombotic therapy Post-TAVI antithrombotic therapy varies depending upon the following factors (algorithm 1): Presence of a concurrent indication for anticoagulation (such as atrial fibrillation [AF] with criteria for anticoagulation)
What is the current optimal antithrombotic therapy after transcatheter . . . Antiplatelet therapy is generally preferred over anticoagulation therapy as an antithrombotic strategy after TAVI Single antiplatelet therapy (SAPT) is a preferable option over dual antiplatelet therapy (DAPT) in reducing bleeding events
Duration of Antiplatelet Therapy Following Transcatheter Aortic Valve . . . Although current guidelines recommend dual antiplatelet therapy (DAPT) for 3 to 6 months following transcatheter aortic valve replacement (TAVR), there are no studies directly comparing outcomes of different durations of DAPT following TAVR
Optimal antithrombotic therapy after transcatheter aortic valve . . . Transcatheter aortic valve replacement (TAVR) has become a leading treatment for aortic stenosis, but managing thromboembolic and bleeding risks post-procedure remains challenging This review examines current evidence on antithrombotic therapy after TAVR
Antithrombotic Therapy After Transcatheter Aortic Valve Replacement If a patient undergoes TAVR in the context of a recent or concomitant PCI, a mandatory period of DAPT is required on the basis of the clinical presentation (eg, 6 months after elective PCI, 12 months after PCI for acute coronary syndromes, with halved durations in patients at high bleeding risk)